StreetInsider.com News Articles

Quoin Pharma forms Japan subsidiary to advance QRX003 commercialization

Thu, 18 Jun 2026 08:31:44 -0400

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) has established a wholly-owned subsidiary in Japan as part of its plan to directly commercialize QRX003, a treatment candidate for Netherton Syndrome, if the drug receives regulatory approval.

The subsidiary formation follows Japan's Ministry of Health, Labour and Welfare granting Orphan Drug Designation to QRX003. The drug has now received Orphan Drug Designation in the United States, the European Union, and Japan — covering all three of Quoin's core commercial territories.

Japan joins the U.S. and Western Europe as markets where Quoin intends to self-commercialize QRX003. The company previously established Quoin Therapeutics Ireland as its Western European

Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003

Thu, 18 Jun 2026 08:30:00 -0400

Supports Quoin’s planned direct commercialization of QRX003 in Japan, one of its three core commercial territories

Follows recent grant of Orphan Drug Designation to QRX003 by Japan’s MHLW

ASHBURN, Va., June 18, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (“Quoin” or the “Company”), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today announced that it has completed the establishment of a wholly-owned subsidiary in Japan as part of its strategy to directly commercialize QRX003 for the treatment of Netherton Syndrome, if approved. The formation follows the recent grant of Orphan

Quoin Pharmaceuticals Completes Establishment of Japanese Subsidiary to Advance Commercial Readiness for QRX003

Thu, 18 Jun 2026 08:30:00 -0400

Supports Quoin’s planned direct commercialization of QRX003 in Japan, one of its three core commercial territories

Follows recent grant of Orphan Drug Designation to QRX003 by Japan’s MHLW

Quoin Pharmaceuticals reports 4 of 6 patients improved in NS compassionate use trial

Tue, 16 Jun 2026 08:31:32 -0400

Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) reported that four of six pediatric patients enrolled in its Netherton Syndrome (NS) compassionate use program showed improvement from baseline across key clinical endpoints, according to a press release dated June 16, 2026.

All six patients are under 10 years of age, with the youngest being six months old. Treatment duration ranges from three weeks to 15 months. No treatment-related adverse events have been reported for any of the six patients.

Three of the four responding patients achieved at least a one-grade improvement on the Investigator's Global Assessment (IGA) scale of 0 to 4. One patient improved

Quoin Pharmaceuticals reports 4 of 6 patients improved in NS compassionate use trial

Tue, 16 Jun 2026 08:31:32 -0400

Three of the four responding patients achieved at least a one-grade improvement on the Investigator's Global Assessment (IGA) scale of 0 to 4. One patient improved

Quoin Pharmaceuticals reports 4 of 6 patients improved in NS compassionate use trial

Tue, 16 Jun 2026 08:31:32 -0400

Three of the four responding patients achieved at least a one-grade improvement on the Investigator's Global Assessment (IGA) scale of 0 to 4. One patient improved

Quoin Pharmaceuticals reports 4 of 6 patients improved in NS compassionate use trial

Tue, 16 Jun 2026 08:31:32 -0400

Three of the four responding patients achieved at least a one-grade improvement on the Investigator's Global Assessment (IGA) scale of 0 to 4. One patient improved

Quoin Pharmaceuticals Announces Positive Clinical Update from Ongoing Pediatric Netherton Syndrome Compassionate Use Program

Tue, 16 Jun 2026 08:30:00 -0400

Four of Six Patients Participating in the Compassionate Use Program Were Classified as ‘Improved’ or ‘Significantly Improved’ from Baseline Assessment Across Key Clinical Endpoints

All Six Patients Are Younger than 10 Years of Age, with the Youngest Being Just 6 Months Old
Duration of Treatment To-Date Ranges from 3 Weeks to 15 Months
No Treatment Related Adverse Events Reported for All Six Patients
Additional Pediatric Patients Enrolling in Program in June and September
Quoin Plans a Comprehensive Data Release, including from Ongoing Phase 2 Studies, in the Coming Months